FI3978074T3 - Terlipressiini tyypin 1 hepatorenaalisen syndrooman hoitamiseksi - Google Patents
Terlipressiini tyypin 1 hepatorenaalisen syndrooman hoitamiseksi Download PDFInfo
- Publication number
- FI3978074T3 FI3978074T3 FIEP21205752.5T FI21205752T FI3978074T3 FI 3978074 T3 FI3978074 T3 FI 3978074T3 FI 21205752 T FI21205752 T FI 21205752T FI 3978074 T3 FI3978074 T3 FI 3978074T3
- Authority
- FI
- Finland
- Prior art keywords
- terlipressin
- patient
- treatment
- blood
- serum creatinine
- Prior art date
Links
- 108010010056 Terlipressin Proteins 0.000 title claims 9
- BENFXAYNYRLAIU-QSVFAHTRSA-N terlipressin Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CN)CSSC1 BENFXAYNYRLAIU-QSVFAHTRSA-N 0.000 title claims 9
- 229960003813 terlipressin Drugs 0.000 title claims 9
- 201000011200 hepatorenal syndrome Diseases 0.000 title claims 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims 8
- 210000004369 blood Anatomy 0.000 claims 4
- 239000008280 blood Substances 0.000 claims 4
- 229940109239 creatinine Drugs 0.000 claims 4
- 210000002966 serum Anatomy 0.000 claims 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 238000004820 blood count Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
- A61B5/0205—Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
- A61B5/024—Measuring pulse rate or heart rate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/14542—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue for measuring blood gases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M27/00—Drainage appliance for wounds or the like, i.e. wound drains, implanted drains
- A61M27/002—Implant devices for drainage of body fluids from one part of the body to another
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
- G01N33/4925—Blood measuring blood gas content, e.g. O2, CO2, HCO3
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/01—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
- G01N2015/016—White blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N2015/1024—Counting particles by non-optical means
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Analytical Chemistry (AREA)
- Cardiology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Physiology (AREA)
- Surgery (AREA)
- Medical Informatics (AREA)
- Ecology (AREA)
- Food Science & Technology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Dispersion Chemistry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462068357P | 2014-10-24 | 2014-10-24 | |
| US201562151384P | 2015-04-22 | 2015-04-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3978074T3 true FI3978074T3 (fi) | 2024-05-20 |
Family
ID=54478246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP21205752.5T FI3978074T3 (fi) | 2014-10-24 | 2015-10-22 | Terlipressiini tyypin 1 hepatorenaalisen syndrooman hoitamiseksi |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10335452B2 (OSRAM) |
| EP (3) | EP3978074B1 (OSRAM) |
| JP (4) | JP6673915B2 (OSRAM) |
| CN (2) | CN107206049B (OSRAM) |
| AU (1) | AU2015335855A1 (OSRAM) |
| CA (1) | CA2965325A1 (OSRAM) |
| DK (2) | DK3978074T3 (OSRAM) |
| ES (2) | ES2987577T3 (OSRAM) |
| FI (1) | FI3978074T3 (OSRAM) |
| HR (1) | HRP20220225T1 (OSRAM) |
| HU (1) | HUE058066T2 (OSRAM) |
| PL (2) | PL3978074T3 (OSRAM) |
| PT (2) | PT3978074T (OSRAM) |
| SI (1) | SI3209317T1 (OSRAM) |
| WO (1) | WO2016065117A1 (OSRAM) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3058497T3 (en) | 2008-09-17 | 2026-03-11 | Amryt Endo Inc | Pharmaceutical compositions comprising polypeptides and related methods of delivery |
| US20200046798A1 (en) * | 2014-10-24 | 2020-02-13 | Mallinckrodt Hospital Products IP Limited | Method of treating patients with hepatorenal syndrome type 1 |
| CN107206049B (zh) * | 2014-10-24 | 2021-12-07 | 马林克罗特医疗产品知识产权公司 | 治疗患1型肝肾综合征的患者的方法 |
| US20210290725A1 (en) * | 2014-10-24 | 2021-09-23 | Mallinckrodt Pharmaceuticals Ireland Limited | Method of treating patients with hepatorenal syndrome type 1 |
| IL313083A (en) | 2016-10-21 | 2024-07-01 | Amryt Endo Inc | Terlipressin compositions and their methods of use |
| KR20220011697A (ko) | 2019-05-22 | 2022-01-28 | 바이오비에 아이앤씨. | 테를리프레신 제형 |
| CN110251469B (zh) * | 2019-07-31 | 2021-11-09 | 南京康舟医药科技有限公司 | 一种醋酸特利加压素制剂及其制备方法 |
| KR20220092868A (ko) * | 2019-10-30 | 2022-07-04 | 말린크로트 호스피탈 프로덕츠 아이피 언리미티드 캄파니 | 제1형 간신증후군 및 낮은 평균 동맥압 환자의 치료 방법 |
| WO2023183339A1 (en) * | 2022-03-22 | 2023-09-28 | Ocelot Bio, Inc. | Selective vasopressin receptor agonist for end-stage liver disease |
| US20240156895A1 (en) * | 2022-10-28 | 2024-05-16 | Mallinckrodt Pharmaceuticals Ireland Limited | Compositions for improving kidney function in patients with hepatorenal syndrome |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1188443A1 (en) | 2000-09-15 | 2002-03-20 | Ferring BV | Improved protocol for paracentesis |
| US7785857B2 (en) * | 2006-08-31 | 2010-08-31 | Saint Louis University | Protein C variant |
| GB0617581D0 (en) * | 2006-09-07 | 2006-10-18 | Ucl Business Plc | Biomarkers for assessing liver function |
| WO2008112563A1 (en) * | 2007-03-09 | 2008-09-18 | Flowmedica, Inc. | Acute kidney injury treatment systems and methods |
| US9050286B2 (en) | 2007-08-14 | 2015-06-09 | Ferring B.V. | Use of peptidic vasopression receptor agonists |
| JP5752600B2 (ja) * | 2008-11-10 | 2015-07-22 | アスチュート メディカル，インコーポレイテッド | 腎損傷および腎不全の診断および予後のための方法 |
| US20100260739A1 (en) | 2009-03-09 | 2010-10-14 | Bioatla, Llc | Mirac Proteins |
| EP2440200B8 (en) | 2009-06-08 | 2014-10-15 | UCL Business PLC | Treatment of portal hypertension using l-ornithine phenylacetate |
| AU2011279144A1 (en) * | 2010-07-14 | 2013-01-24 | Cumberland Emerging Technologies, Inc | Methods of treating hepatorenal syndrome and hepatic encephalopathy with thromboxane-A2 receptor antagonists |
| JP2012159356A (ja) * | 2011-01-31 | 2012-08-23 | Mochida Pharmaceut Co Ltd | 敗血症診断用組合せマーカー |
| CN103254295A (zh) * | 2013-05-31 | 2013-08-21 | 青岛国大生物制药股份有限公司 | 特利加压素的制备方法 |
| CN107206049B (zh) * | 2014-10-24 | 2021-12-07 | 马林克罗特医疗产品知识产权公司 | 治疗患1型肝肾综合征的患者的方法 |
| JP2017014206A (ja) | 2015-06-30 | 2017-01-19 | ナノアンティバイオティクス，インコーポレイテッド | 腹水の治療 |
-
2015
- 2015-10-22 CN CN201580062745.3A patent/CN107206049B/zh active Active
- 2015-10-22 WO PCT/US2015/056861 patent/WO2016065117A1/en not_active Ceased
- 2015-10-22 EP EP21205752.5A patent/EP3978074B1/en active Active
- 2015-10-22 AU AU2015335855A patent/AU2015335855A1/en not_active Abandoned
- 2015-10-22 ES ES21205752T patent/ES2987577T3/es active Active
- 2015-10-22 PT PT212057525T patent/PT3978074T/pt unknown
- 2015-10-22 US US14/920,392 patent/US10335452B2/en active Active
- 2015-10-22 HR HRP20220225TT patent/HRP20220225T1/hr unknown
- 2015-10-22 ES ES15791430T patent/ES2904492T3/es active Active
- 2015-10-22 EP EP15791430.0A patent/EP3209317B1/en active Active
- 2015-10-22 DK DK21205752.5T patent/DK3978074T3/da active
- 2015-10-22 DK DK15791430.0T patent/DK3209317T3/da active
- 2015-10-22 CN CN202111342532.XA patent/CN114028536B/zh active Active
- 2015-10-22 EP EP21208813.2A patent/EP3981420A1/en active Pending
- 2015-10-22 PT PT157914300T patent/PT3209317T/pt unknown
- 2015-10-22 HU HUE15791430A patent/HUE058066T2/hu unknown
- 2015-10-22 JP JP2017521988A patent/JP6673915B2/ja active Active
- 2015-10-22 FI FIEP21205752.5T patent/FI3978074T3/fi active
- 2015-10-22 PL PL21205752.5T patent/PL3978074T3/pl unknown
- 2015-10-22 PL PL15791430T patent/PL3209317T3/pl unknown
- 2015-10-22 SI SI201531790T patent/SI3209317T1/sl unknown
- 2015-10-22 CA CA2965325A patent/CA2965325A1/en not_active Abandoned
-
2019
- 2019-05-14 US US16/411,944 patent/US20190328831A1/en not_active Abandoned
- 2019-08-28 JP JP2019155678A patent/JP6989571B2/ja active Active
-
2021
- 2021-06-21 JP JP2021102221A patent/JP7346494B2/ja active Active
-
2022
- 2022-09-14 JP JP2022146052A patent/JP2022171795A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| PL3978074T3 (pl) | 2024-08-12 |
| JP2017534618A (ja) | 2017-11-24 |
| ES2904492T3 (es) | 2022-04-05 |
| ES2987577T3 (es) | 2024-11-15 |
| DK3209317T3 (da) | 2022-02-07 |
| EP3209317A1 (en) | 2017-08-30 |
| CN114028536A (zh) | 2022-02-11 |
| WO2016065117A1 (en) | 2016-04-28 |
| JP6989571B2 (ja) | 2022-01-05 |
| DK3978074T3 (da) | 2024-05-13 |
| EP3209317B1 (en) | 2021-12-08 |
| JP2022171795A (ja) | 2022-11-11 |
| CN107206049A (zh) | 2017-09-26 |
| JP7346494B2 (ja) | 2023-09-19 |
| EP3978074A1 (en) | 2022-04-06 |
| HRP20220225T1 (hr) | 2022-04-29 |
| CA2965325A1 (en) | 2016-04-28 |
| AU2015335855A1 (en) | 2017-05-18 |
| JP6673915B2 (ja) | 2020-03-25 |
| US10335452B2 (en) | 2019-07-02 |
| EP3978074B1 (en) | 2024-03-06 |
| JP2021155433A (ja) | 2021-10-07 |
| CN114028536B (zh) | 2024-07-09 |
| PL3209317T3 (pl) | 2022-05-23 |
| JP2019199485A (ja) | 2019-11-21 |
| PT3978074T (pt) | 2024-05-13 |
| EP3981420A1 (en) | 2022-04-13 |
| US20160113994A1 (en) | 2016-04-28 |
| SI3209317T1 (sl) | 2022-05-31 |
| HUE058066T2 (hu) | 2022-06-28 |
| PT3209317T (pt) | 2022-01-19 |
| CN107206049B (zh) | 2021-12-07 |
| US20190328831A1 (en) | 2019-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201201284A1 (ru) | Система для обработки крови | |
| EP3372685A3 (en) | Cell lines for virus production and methods of use | |
| MY174894A (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation | |
| WO2015118537A3 (en) | Micro-rnas and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions | |
| WO2016193929A3 (en) | Injecting and monitoring nervous tissue | |
| EP2759332A4 (en) | WATER TREATMENT MEMBRANE HAVING HIGH CHLORINE RESISTANCE AND HIGH PERMEABILITY, AND METHOD OF MANUFACTURING THEREOF | |
| MX382754B (es) | Terapias combinadas para tratar el cancer. | |
| EA201400274A1 (ru) | Связующая молекула, обладающая нейтрализующей активностью в отношении вируса гриппа а, полученная из в-клеток человека | |
| WO2014152754A3 (en) | Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens | |
| PH12013502144A1 (en) | Multiple myeloma treatment | |
| AU2018260858A1 (en) | Perm selective membrane for treating vascular calcification in chronic hemodialysis patients | |
| MX2020011190A (es) | Angiotensina ii sola o en combinacion para usarse en el tratamiento de hipotension. | |
| MX373524B (es) | Solución estabilizada de ácido hipocloroso y uso de la misma. | |
| TN2016000083A1 (en) | Methods and tools relating to the administration of contrast medium | |
| EA202193276A1 (ru) | Способы лечения холангиокарциномы | |
| EA201390925A1 (ru) | Производные санглиферина и способы их получения | |
| NZ702666A (en) | A method of weight reduction | |
| JOP20210347A1 (ar) | طرق لعلاج فيروس نقص المناعة البشرية | |
| RU2010141064A (ru) | Способ лечения папилломавирусных инфекций, реализуемый через индукцию интерлейкина - 18 | |
| MX2022004157A (es) | Metodo de tratamiento de pacientes con sindrome hepatorrenal tipo 1 y presion arterial media baja. | |
| MX2016011002A (es) | Tratamiento de angioedema hereditario con inhibidor c1. | |
| DING et al. | Effect of Lipoic Acid Treatment on Endothelial Microparticles in Patients with Diabetic Peripheral Artery Disease in Lower Limbs | |
| RU2012110137A (ru) | Способ лечения инсулинорезистентности | |
| RU2011111808A (ru) | Способ биологизированной защиты винограда от болезней | |
| RU2014142756A (ru) | Способы воздействия на экспрессию гена D4DR |